Moneycontrol PRO
you are here: HomeNewsBusiness

Buy Sanofi India; target of Rs 9750: ICICI Direct

ICICI Direct is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9750 in its research report dated July 28, 2021.

July 29, 2021 / 02:29 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Sanofi India

Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, thrombosis, anti-infective, CNS, allergy, vitamins, minerals & supplements. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India Sanofi is one of the fastest growing companies in India in anti-diabetic therapy


We remain positive and retain our BUY rating on the stock We value Sanofi at Rs 9750 i.e. 35x P/E on FY23E EPS

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jul 29, 2021 02:29 pm
ISO 27001 - BSI Assurance Mark